Chengdu Shiliankangjian Biotechnology

Chengdu Shiliankangjian Biotechnology is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, dedicated to the development of innovative peptide and small molecule drugs. The company focuses on metabolic disorders and oncology, utilizing its proprietary technology platforms to design multi-target agonists with improved efficacy and safety profiles. Its lead program, SLKJ-0603, is a long-acting triple agonist targeting the GLP-1, GIP, and glucagon receptors, currently in clinical trials for obesity and type 2 diabetes. Beyond metabolic health, the company is advancing a pipeline of small molecule candidates for various cancer indications. Shiliankangjian leverages strong regional support from the Chengdu Bio-town to accelerate its research and development efforts.